Studies Directed at Maximising Achievement of Treatment Free Remission in CML

慢性粒细胞白血病（CML）通常可以有效地治疗与长期酪氨酸激酶抑制剂（TKI）治疗。值得注意的是，极少数达到良好反应的患者可以完全停止治疗而不会复发。对这些患者的遗传背景、白血病生物学和免疫反应进行详细研究，可能有助于我们了解这是如何实现的，从而找到新的治疗方法，使免治疗缓解更广泛地实现。

Chronic myeloid leukaemia (CML) can usually be treated effectively with long-term tyrosine kinase inhibitor (TKI) therapy. Remarkably, rare patients who achieve excellent responses can stop treatment altogether without relapsing. Detailed studies of these patients in terms of their genetic background, the biology of their leukaemia and their immune response may help us understand how this is possible, leading to new therapeutic approaches to make treatment-free remission more widely achievable.